Physician profile
Courtney E Glos
NPI 1053760728
$2,186.95
in general payments reported to CMS, 2019-2025
23 companies · $124 in 2025
The $124 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.22 · 2020: $14.22 · 2021: $56.39 · 2022: $1,314 · 2023: $439 · 2024: $183 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446 · Honoraria: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.83 |
| Honoraria | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Parapro, LLC | $1,300.00 | 2022-2023 | Natroba |
| Supernus Pharmaceuticals, INC. | $161.77 | 2022-2025 | Qelbree |
| Abbvie INC. | $113.77 | 2024 | |
| Merck Sharp & Dohme LLC | $110.15 | 2021-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Ironshore Pharmaceuticals INC. | $71.14 | 2022 | |
| Voco America INC. | $40.36 | 2024 | Grandio Seal, Voco Profluorid Varnish, Admira Fusion X-Tra |
| Sobi, INC | $39.41 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $34.83 | 2023-2024 | Flumist Quadrivalent, Breztri |
| Glaxosmithkline, LLC. | $31.93 | 2019-2025 | Bexsero, Penmenvy, Shingrix |
| Inspire Medical Systems, INC. | $31.86 | 2023 | Inspire |
| Cipher Pharmaceuticals US LLC | $29.52 | 2025 | Spinosad, Natroba |
| Sanofi Pasteur INC. | $29.21 | 2020-2021 | |
| Tris Pharma INC | $27.07 | 2021-2022 | |
| Abbott Laboratories | $22.02 | 2023 | Freestyle Libre 3 |
| Organon LLC | $19.99 | 2025 | Nexplanon |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18.28 | 2023 | Mounjaro |
| Genentech USA, INC. | $18.15 | 2019 | |
| Pfizer INC. | $16.16 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.57 | 2023 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $14.55 | 2024 | Uptravi, Opsumit |
| Corium, LLC | $14.50 | 2025 | Azstarys |
| Exact Sciences Corporation | $13.52 | 2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Courtney Glos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.